Baidu
map

Angew Chem Int Ed Engl:深圳先进院成功开发癌症活性磷疗新技术

2018-12-02 佚名 深圳先进院

近日,中国科学院深圳先进技术研究院研究员喻学锋课题组在开发天然生物活性纳米化疗药物领域取得新进展。相关工作“Rediscovery of Black Phosphorus: Bioactive Nanomaterials with Inherent and Selective Chemotherapeutic Effects”(《基于黑磷的活性磷疗——一种天然生物活性纳米化疗药物的新发现》)发表于

近日,中国科学院深圳先进技术研究院研究员喻学锋课题组在开发天然生物活性纳米化疗药物领域取得新进展。相关工作“Rediscovery of Black Phosphorus: Bioactive Nanomaterials with Inherent and Selective Chemotherapeutic Effects”(《基于黑磷的活性磷疗——一种天然生物活性纳米化疗药物的新发现》)发表于《德国应用化学》。

癌症作为目前全球主要致死原因之一,对患者、家庭和社会造成了巨大负担。随着纳米技术的飞速发展,各类新型纳米材料为癌症的治疗提供了新的思路和方法。然而,目前围绕纳米材料的肿瘤治疗研究仍主要基于对其物理性能的开发,而对于纳米材料在与细胞内环境相互作用时产生的生物活性则仅被认为是一种生物毒性作用而被忽视。针对这一问题,喻学锋课题组以黑磷为模型,通过深入研究其化学生物活性,揭示了其作为高选择性纳米化疗药物的潜能。

黑磷作为一种新型二维材料,因其良好的生物活性和生物相容性,以及其优越的光学特性,在生物医学领域受到广泛关注。喻学锋课题组在之前的研究中已成功将黑磷纳米材料应用于肿瘤光热治疗(Nature Communications, 2016, 7, 12967)、植入材料(Biomaterials, 2018, 164, 11; Advanced Science, 2018, 5, 1700848)以及生物活性大分子的细胞转运(Angewandte Chemie International Edition, 2018, 57, 10268)等领域。基于这些前期工作,以及在这些工作中发现的黑磷在生理环境下复杂的降解过程和多样的活性中间产物,团队深入探讨了黑磷纳米片在细胞内降解过程的机理和可能诱发的生物学效应。

课题组研究发现,由于癌细胞旺盛的胞吞作用、较快的代谢速率和较强的氧化压力,黑磷纳米片易被癌细胞通过胞吞作用大量摄取,并被快速降解,在胞内产生大量磷酸根离子。这一过程导致癌细胞内环境改变,引起G2/M期阻滞,从而抑制癌细胞增殖。增殖抑制后的癌细胞进一步通过凋亡和自噬的途径进入程序化细胞死亡。而对于正常细胞,由于其较弱的摄取活性和代谢速率,黑磷的摄取少且降解缓慢,从而保持了很高的生物相容性。深入的细胞和动物实验表明,黑磷纳米片展现出优异的抗肿瘤功效,其对癌细胞的选择性杀伤作用远优于传统化疗药物阿霉素(DOX)。

课题组将这一源自黑磷天然生物活性的癌细胞选择性杀伤作用称为“生物活性磷基药物疗法(Bioactive Phosphorus-based Therapy)”,简称“活性磷疗 (BPT)”。该研究不仅展示了黑磷在纳米化疗药物开发领域的巨大前景,同时也揭示了纳米材料在肿瘤治疗研究领域的新方向。

该研究工作得到中科院前沿科学研究重点计划、国家自然科学基金、深圳市科技计划国际合作研究、相关研究资助局面上项目和香港城市大学战略研究项目的支持。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903822, encodeId=61d71903822cd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Aug 04 10:22:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779937, encodeId=9bda1e79937a5, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 08 15:22:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785540, encodeId=894d1e85540ba, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Aug 17 09:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081509, encodeId=ffeb2081509d3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Aug 17 22:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903822, encodeId=61d71903822cd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Aug 04 10:22:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779937, encodeId=9bda1e79937a5, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 08 15:22:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785540, encodeId=894d1e85540ba, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Aug 17 09:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081509, encodeId=ffeb2081509d3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Aug 17 22:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-11-08 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903822, encodeId=61d71903822cd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Aug 04 10:22:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779937, encodeId=9bda1e79937a5, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 08 15:22:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785540, encodeId=894d1e85540ba, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Aug 17 09:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081509, encodeId=ffeb2081509d3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Aug 17 22:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-17 haouestc
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903822, encodeId=61d71903822cd, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Aug 04 10:22:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779937, encodeId=9bda1e79937a5, content=<a href='/topic/show?id=d8e32515d1' target=_blank style='color:#2F92EE;'>#Angew#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2515, encryptionId=d8e32515d1, topicName=Angew)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 08 15:22:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785540, encodeId=894d1e85540ba, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Aug 17 09:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081509, encodeId=ffeb2081509d3, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Aug 17 22:22:00 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-17 spoonycyy

相关资讯

Nature Biotech:DNA纳米机器人精准靶向癌症

我们目前对抗恶性肿瘤的方法还远远不够,常见的化疗和放射治疗有时很成功,但也会带来巨大的副作用。这主要是因为体内的健康细胞也会被“连累”受到化学物质和辐射的“轰击”。

Adv. Mater:上海药物所实现光控药物胞浆递送和肿瘤的可视化治疗

细胞毒性T细胞具有特异性杀伤异常细胞的能力,在肿瘤治疗中发挥着重要作用。嵌合抗原受体-T细胞(CAR-T)的发明进一步拓宽了其在肿瘤治疗领域的应用。然而,细胞毒性T细胞在体内的行为难以监测和调控,在实体瘤治疗中由于免疫微环境的存在疗效有限,且需要从患者提取T细胞进行修饰,规模化制备受限。

JACC:腹主动脉瘤新型纳米疗法的开发

腹主动脉瘤(AAA)是老年死亡和并发症的主要原因之一,目前尚无能有效阻止AAA生长和破裂的药物。本研究的目的旨在开发出一种靶向动脉瘤释放抗炎症因子药物的纳米疗法。本研究的纳米疗法是将活性氧(ROS)响应纳米粒子与候选药物分子雷帕霉素结合起来,并在体外和体内进行了效果的验证。该纳米颗粒会在富含ROS的表面释放药物分子,在与AAA发病相关的细胞中,该纳米疗法可以明显减少钙化水平和ROS介导的细胞凋亡水

Nat Commun:上海药物所领衔团队在生物纳米材料领域取得新突破

2018年7月4日,《自然-通讯》杂志以“Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers”为题,在线报道了中科院上海药物所和国家纳米科学中心合作的最新研究成果。

Trends Biotechnol:安全有效使用纳米材料抗癌?肿瘤异质性至关重要!

纳米粒子抗癌疗法日趋火热,而使用该治疗疗法所带来的有效性和安全性问题却有待解决。最新研究表明使用该抗癌疗法必须考虑灌注质量、癌症干细胞等级和可兑换性。其他重要因素还包括表观遗传学改变,增强渗透和保留效应以及网状内皮系统的影响。

Nature Biomedical Engineering:突破!纳米颗粒抗击前列腺癌!抑癌因子被恢复!

根据神刊CA刚刚发布的全球癌症统计报告2018,前列腺癌在男性肿瘤的发病和致死率中均排行前5名。这种发病和致死率均十分高的肿瘤困扰着全球数千万的老年男性。来自布里格姆妇女医院和波士顿儿童医院的研究小组与Memorial Sloan Kettering癌症中心的科研人员利用纳米颗粒开发出一种全新的抑癌方法, 他们通过重新赋予像PTEN和p53等肿瘤抑制因子的功能进而达到减缓前列腺癌的进展。该团队最新

Baidu
map
Baidu
map
Baidu
map